NCT06334211View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 16, 2024

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions
Healthy
Interventions
DRUG

FP-020

MMP-12 inhibitor

OTHER

placebo

placebo

Trial Locations (1)

2031

Scientia Clinical Research Ltd, Randwick

Sponsors
All Listed Sponsors
collaborator

InClin, Inc.

UNKNOWN

lead

Foresee Pharmaceuticals Co., Ltd.

INDUSTRY